Form 8-K - Current report:
SEC Accession No. 0001367644-22-000132
Filing Date
2022-08-12
Accepted
2022-08-12 17:03:45
Documents
15
Period of Report
2022-08-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20220812.htm   iXBRL 8-K 36128
2 EX-99 emergent081222statement.htm EX-99 2613
7 GRAPHIC emergent081222statement001.jpg GRAPHIC 170191
  Complete submission text file 0001367644-22-000132.txt   427680

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20220812.xsd EX-101.SCH 2218
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20220812_def.xml EX-101.DEF 2933
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20220812_lab.xml EX-101.LAB 27198
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20220812_pre.xml EX-101.PRE 14705
9 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20220812_htm.xml XML 11025
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 221161098
SIC: 2834 Pharmaceutical Preparations